If you have been reading about Heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
== Further reading == Booth, Martin (2004). Cannabis: A History. Picador. ISBN 978-0-312-42494-7. Drake, Bill (2002). The Marijuana Food Handbook: A Guide for the Sensuous Connoisseur. Ronin Publishing. ISBN 978-0-914171-99-7. Grinspoon, Lester (1994). Marihuana Reconsidered. Quick American Archives. ISBN 978-0-932551-13-9.
Representatives Gary Peters (D-MI) and Iowa Republican Senator Joni Ernst emphasized the role of supply chain breakdowns and weak points in medication shortages. They also argued that U.S. "over-reliance" on foreign nations for key ingredients would lead to future shortages out of American control, especially for dependence on "foreign adversaries" and "bad actors", with China named as an example. Dr. Stephen Schondelmeyer further stated that while the number of pharmaceutical production facilities in the United States was cut in half since 2014, the numbers of pharmaceutical plants were steadily growing in several countries such as Taiwan, India, Israel, and China. He reported that China and India's conditions for pharmaceutical production were greatly enhanced by having less environmental regulations and cheaper labor.
=== Enterocytes and incretin === While glucokinase has been shown to occur in certain cells (enterocytes) of the small intestine and stomach, its function and regulation have not been worked out. It has been suggested that here, also, glucokinase serves as a glucose sensor, allowing these cells to provide one of the earliest metabolic responses to incoming carbohydrates. It is suspected that these cells are involved in incretin functions.
It was remarkable, how, after the war, this rather unassuming scientist who had spent a lifetime in the laboratory, became an effective administrator and an important public figure in Germany. Hahn, famous as the discoverer of nuclear fission, was respected and trusted for his human qualities, simplicity of manner, transparent honesty, common sense and loyalty.
Sources: en.wikipedia.org
2023, Overseas Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE) 2019, Othmer Gold Medal, Science History Institute and others 2018, honorary Doctorate, Utrecht University 2017, Catalyst Award, Science Club for Girls 2015, Heinz Award, Heinz Family Foundation, in the Technology, the Economy and Employment category "for her seminal work in tissue engineering and disease detection, including the cultivation of functional liver cells outside of the human body, and for her passion in promoting the advancement of women in the STEM fields." 2014, Lemelson-MIT Prize, Massachusetts Institute of Technology "for her dedication to the next generation of scientists, and groundbreaking inventions to improve human health and patient care on a global scale." 2011, BEAM (Brown Engineering Alumni Medal) Award, Brown University School of Engineering 2008, Howard Hughes Medical Institute investigator 1999, Packard Fellowship, David and Lucile Packard Foundation
=== Blood test === see also: blood doping The blood test detects illegal performance enhancement drugs through the measurement of indicators that change with the use of recombinant human erythropoietin:
== Career == King joined Massachusetts Institute of Technology in 1959 as an assistant professor of chemical engineering to become director of the School of Chemical Engineering Practice station at the Exxon (then Esso) Bayway refinery in New Jersey. In 1963, King joined University of California, Berkeley as assistant professor of chemical engineering, becoming associate professor in 1966 and full professor in 1969. From 1967 to 1972, he served as the vice chairman of Department of Chemical Engineering. He then served as the chairman of the department from 1972 to 1981. In 1981, King was appointed as the dean of College of Chemistry and later in 1987 as the provost of the Professional Schools and Colleges, a position in which he served until 1994. At the time of his appointment, King was the first chemical engineer to become dean of the College of Chemistry at Berkeley. King was appointed the vice provost for research for the entire nine-campus University of California in 1994. In 1995 he became provost and senior vice president for academic affairs, again university-wide. During his time as UC provost, King helped launch the new, tenth UC campus at Merced, the California Digital Library, and eScholarship, the University of California's open access, electronic repository for publications by UC authors. He returned to UC Berkeley in 2004 as the director of Center for Studies in Higher Education, serving in this position for a full decade until 2014.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.